Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction. by Fabris, C. et al.
Br. J. Cancer (1991), 63, 451 453 t~~~~~~~~~~~~~~Macmillan Press Ltd., 1991~~~~~~~~~
Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer:
influence ofjaundice and liver dysfunction
C. Fabris', A. Malesci2, D. Basso', C. Bonato2, G. Del Favero', M. Tacconi2, T. Meggiato',
P. Fogar', M.P. Panozzoi, C. Ferrara', P. Scalon' & R. Naccarato'
iIstituto di Medicina Interna (Cattedra di Malattie Apparato Digerente) Universita degli Studi di Padova; 2Istituto di Clinica
Medica 3, Ospedale Maggiore, Milano, Italy.
Summary The usefulness of serum DU-PAN-2 in diagnosing pancreatic cancer and in distinguishing between
this cancer and other benign and malignant diseases, and to assess the role of liver dysfunction in altering the
serum levels of this marker were investigated. DU-PAN-2 was measured in the sera of 31 patients with
pancreatic cancer, 32 with chronic pancreatitis, 20 with benign and 21 with malignant extra-pancreatic
diseases. DU-PAN-2 was found to be above 300 U ml-' in 21/31 patients with pancreatic cancer (sensitivity
68%). Only 3/32 patients with chronic pancreatitis had abnormal values. A substantial number of patients
with both benign and malignant extra-pancreatic diseases had an elevated serum DU-PAN-2 (9/20 and 15/21,
respectively). Correlations were found between DU-PAN-2 and (1) total bilirubin, (2) alanine-amino-trans-
ferase and (3) alkaline phosphatase. Of the patients with high DU-PAN-2 values, jaundice was found in: 2/3
with chronic pancreatitis, 9/10 with benign and 12/14 with malignant extra-pancreatic diseases. In conclusion,
the serum DU-PAN-2 test for pancreatic malignancy is not completely satisfactory, because it is not sensitive
enough. While the test for chronic pancreatitis has an acceptable specificity, the assay cannot distinguish
between pancreatic cancer and other extra-pancreatic diseases, mainly of the liver and biliary tract. Liver
dysfunction as well as jaundice seem to considerable affect the levels of this marker, as reported elsewhere for
CA 19-9.
A human pancreatic adenocarcinoma associated antigen,
DU-PAN-2, has recently been partially characterised (Metz-
gar et al., 1984; Lan et al., 1985).
Analytical studies performed indicate that DU-PAN-2 epi-
tope is expressed on a mucin-like molecule (Lan et al., 1985;
Lan et al., 1987). However, the exact nature of this antigen is
not yet well understood.
As DU-PAN-2 is easily measured in body fluids such as
serum, ascites and pancreatic secretions, it has been investi-
gated in different diseases in an attempt to clarify its behav-
iour and utility as a tumour marker (Metzgar et al., 1984).
The reports available in the literature (Metzgar et al., 1984;
Sawabu et al., 1986; Mahvi et al., 1988; Suzuki et al., 1988)
demonstrate that a substantial number of patients with pan-
creatic cancer have high DU-PAN-2 values. However, the
specificity of this assay in the differential diagnosis of pan-
creatic cancer requires further clarification, especially in view
of the fact that serum glycoproteic markers may vary in
relation to multiple factors, such as disease stage, liver dys-
function and jaundice (Del Favero et al., 1986; Basso et al.,
1988a; Fabris et al., 1988).
The aim of this study was to investigate DU-PAN-2 serum
variations in a group of patients with pancreatic cancer, with
respect to patients with chronic pancreatitis and other benign
and malignant extra-pancreatic digestive diseases. We also
ascertained whether DU-PAN-2 variations in the sera of
patients with malignant and benign diseases are attributable
to liver dysfunction and jaundice.
Materials and methods
The study comprised 104 patients. Thirty-one had pancreatic
cancer of duct cell origin (15 males, 16 females, age range
28-79 years) histologically confirmed through the evaluation
of intraoperative or autopsy specimens (Cubilla & Fitzgerald,
1978); 14 had liver metastases. Thirty-two had chronic pan-
creatitis (29 males, three females, age range 29-65 years),
diagnosed on the basis of the clinical picture and on positive
findings from at least two of the following: plain abdomen
X-ray for pancreatic calcifications, ultrasonography, com-
puted axial tomography, endoscopic retrograde pancreato-
graphy. Forty-one patients had extra-pancreatic diseases (22
males, 19 females, age range 39-82 years). The diagnoses
were based on the clinical picture and on the results of
specific radiological and histological procedures: liver cirrho-
sis (seven cases), bile duct cancer (8), benign stenosis of the
papilla of Vater (5), primary liver cell cancer (6), choledo-
cholithiasis (4), carcinoma of the gallbladder (3), colorectal
carcinoma (2), gastric cancer (1), carcinoma of the papilla of
Vater (1), chronic hepatitis (1), gallstones (1), cholesterolosis
of the gallbladder (1), irritable colon (1).
Serum DU-PAN-2 was assayed by means of an EIA using
a commerical kit (Determiner DU-PAN-2, Kyowa Medex
Co. Ltd).
Results were stastically evaluated using the analysis of
variance and analysis of covariance (Anova and Ancova one
way), Bonferroni's test for pairwise comparisons (Wallenstein
et al., 1980), Student's t-test and receiver-operating charac-
teristic (ROC) curves (Weinstein & Fineberg, 1980). Due to
the wide range of values, data were logarithmically trans-
formed for statistical analysis.
Results
Figure 1 shows the individual values for serum DU-PAN-2 in
the groups of patients investigated. The analysis of variance
showed a significant difference among groups (F = 11.5, P<
0.001). Patients with pancreatic cancer and extra-pancreatic
malignancies had higher mean DU-PAN-2 values than
patients with chronic pancreatitis (P<0.005). Patients with
pancreatic cancer and liver metastases had a higher DU-
PAN-2 mean value than those with non-metastatic cancer
(t = 1.89, P<0.05).
Figure 2 illustrates the ROC curves of DU-PAN-2 in
distinguishing between pancreatic cancer patients and the
other groups.
Significant correlations were found between (1) DU-PAN-2
values on the one hand and (2) total bilirubin (r = 0.299,
P<0.01), alkaline-phosphatase (r= 0.522, P<0.001) and
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ml-' jaundice was present in: 2/3 with chronic pancreatitis,
9/10 with benign and 12/14 with malignant extra-pancreatic
diseases.
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C,)
c
z
0L
0
1 800
1 200
600
300i
.
*
0
.
A*
it *
*.- .Ch tl tt8
PC CP EPBD
Figure 1 Individual values of serum DU-PAN-,
groups of patients studied. The continuous lin
upper normal limit according to Suzuki et al. (19
atic cancer; CP: chronic pancreatitis; EPBD:
benign diseases; EPMD: extra-pancreatic malign
metastatic pancreatic cancers.
100-
80
CD
0
20 40 60
False positive results %
Figure 2 ROC curves of DU-PAN-2 in differe
serum value, pancreatic cancer from the other gr
PC: pancreatic cancer; CP: chronic pancreatiti
pancreatic benign diseases; EPMD: extra-panc
diseases.
alanine-amino-transferase (r = 0.438, P<0.001) on the other.
The analyses of covariance were performed considering DU-
PAN-2 as the dependent variable and total bilirubin,
alkaline-phosphatase and alanine-amino-transferase as the
predictor variables. All the three analyses were found to be
significant (F= 8.45, P<0.001; F=3.78, P<0.025; F=
7.41, P<0.001, respectively).
Out of the patients with DU-PAN-2 values of above 300 U
In this study serum DU-PAN-2 values were above 300 U
ml-' (according to Suzuki et al., 1988 who used an EIA
identical to that used in this work) in 68% of patients with
pancreatic cancer. The sensitivity we found was similar to
* that found by other authors in American and Japanese popu-
* lations (Metzgar et al., 1984; Sawabu et al., 1986; Mahvi et
al., 1988); it appears to be lower than that found by us and
others for CA 19-9 (Farini et al., 1985; Malesci et al., 1987;
Steinberg et al., 1986; Sakamoto et al., 1987; Pleskow et al.,
1989). The latter therefore appears preferable in the detection
of pancreatic malignancy. Like other tumour markers, DU-
PAN-2 was found to depend on the tumour's extent, since
the values in patients with liver metastases were higher.
However, it must be born in mind that different, complex
mechanisms regulate serum levels of glycoproteic markers.
Increased DU-PAN-2 values were only occasionally found
in patients with chronic pancreatitis; only one had a value
above 1,000 U ml-'. This result, similar to that found for CA
.0 .19-9, suggests that in the differential diagnosis of a chronic
pancreatic disease, the presence of an extremely high DU-
EPMD PAN-2 value strongly suggests pancreatic cancer.
A large number of patients with benign and malignant
2in the different extra-pancreatic diseases had values of above 300 U ml-',
te represents the and this seems to greatly compromise the diagnostic utility of
)88). PC: pancre- the test. This is confirmed by the ROC curves. DU-PAN-2 is
extra-pancreatic more effective in distinguishing between chronic pancreatic
ant diseases. A, than it is in distinguishing between pancreatic and extra-
pancreatic diseases. Most of the patients with extra-pancre-
atic disease had liver and biliary tract diseases, and these
diseases give rise to difficulty in making a differential diag-
nosis in cases of pancreatic cancer. This suggests that liver
dysfunction may be responsible for the increase in DU-PAN-
2 values in such patients. We found that there were signi-
ficant correlations between DU-PAN-2 and liver function test
values (alkaline-phosphatase, alanine-amino-transferase and
total bilirubin). This observation, in agreement with those of
other authors (Suzuki et al., 1988; Haviland et al., 1988),
suggests that this antigen behaves similarly to CA 19-9.
Elsewhere we demonstrated that serum levels of CA 19-9,
a mucin type molecule, are greatly affected by liver function
alterations (Del Favero et al., 1986; Basso et al., 1988b),
which may increase the values of this antigen. Alterations of
PC vs CP liver function may act through different mechanisms, which
PC EPBD ultimately decrease the uptake, metabolism or excretion of
-PC vsEPMD CA 19-9. Similar results for DU-PAN-2 were found in the
present study. This phenomenon is easily understood because
both antigens are probably epitopes that are co-expressed on
the same mucin molecule, but in varying proportions (Lan et
al., 1987).
80 100 We compared the effect that liver dysfunction and neop-
lasia had in increasing serum DU-PAN-2. Analyses of
covariance suggested that tumour presence had a greater
ntiating, for any influence than liver dysfunction on increases serum DU-
roups of patients. PAN-2 levels.
is; EPBD: extra- We then focused on jaundice, since it may be the first
Sreatic malignant symptom of pancreatic cancer or of other diseases included
in the differential diagnosis. The findings of a higher inci-
dence of a raised DU-PAN-2 in jaundice, already reported
for CA 19-9, indicate that DU-PAN-2 determination is not a
reliable test in a jaundiced patient.
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